AUTHORS: N. Kröger1, F. Ayuk1, D. Atanackovic2, A. Zander1
1 Dept. of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Germany
2 Dept. of Oncology and Hematology, University Hospital Hamburg-Eppendorf, Germany
Donor-lymphocyte infusions (DLI) provide effective treatment for patients who experienced relapse after allogeneic stem cell transplantation. Meanwhile the graft-versus-myeloma effect of DLI is well established. Several attempts had been made in the last years to improve the efficacy of DLI after allogeneic stem cell transplantation for multiple myeloma.